基于文献计量学的国内外免疫检查点抑制剂药物经济学研究趋势与热点分析  

Analysis of Global Pharmacoeconomic Research Trends and Hotspots in Immune Checkpoint Inhibitors Based on Bibliometrics

作　　者：乔元 韩雨倍 姜明欢 赵明月 马方怡 方宇[1] Qiao Yuan;Han Yubei;Jiang Minghuan;Zhao Mingyue;Ma Fangyi;Fang Yu(Department of Pharmacy Administration,School of Pharmacy,Xi’an Jiaotong University,Center for Drug Safety and Policy Research,Xi’an Jiaotong University,International Society for Pharmacoeconomics and Outcomes Research-Northwest China Chapter,Xi’an 710061,China)

机构地区：[1]西安交通大学药学院药事管理学系,西安交通大学药品安全与政策研究中心,国际药物经济与结果研究学会中国西北分会,西安710061

出　　处：《中国药事》2025年第3期280-292,共13页Chinese Pharmaceutical Affairs

摘　　要：目的:采用文献计量学方法分析免疫检查点抑制剂(Immune Checkpoint Inhibitors,ICIs)药物经济学研究领域的热点和趋势,为此类药品综合价值评估、医院药品目录调整、患者合理用药决策和管理政策优化提供参考。方法:检索Web of Science核心合集数据库,检索时限为2011年1月1日至2023年12月31日。运用CiteSpace(6.3.1)、VOSviewer(v1.6.20)、R(v4.3.3)软件和Microsoft Excel 2019版,对纳入文献的发文量、国家、机构、作者、发表期刊、文献共被引、关键词聚类及突变,以及研究主题趋势进行可视化分析。结果与结论:共纳入文献1262篇,年度发文数量及引文量呈现快速上升趋势;总发文量最多的国家是美国,其次是中国,且中国在2022年之后年度发文量已超过美国,但平均被引频次较低;全球开展ICIs药物经济学研究呈现地域差异性,亚洲、非洲以及南美洲部分发展中国家尚为空白。发文量位居第一和第二的机构分别是全球两大生物制药公司百时美施贵宝和默沙东公司;关键词聚类、关键词突变、研究主题趋势分析显示,目前ICIs药物经济学研究主题多数为药物经济学模型研究、患者健康相关生命质量研究。近年来发文较多的是国产创新药的药物经济学研究。未来可进行不同ICIs之间,以及不同联合用药方案之间的成本效果比较,为患者合理用药提供参考;也可运用真实世界数据为药品综合价值评估和目录调整等政策提供依据。Objective:To provide a reference for comprehensive evaluation of drugs,adjustment of hospital drug catalogue,patient medication selection and policy optimization,by conducting a bibliometric study to analyze the research hotspots and trend in the field of pharmacoeconomics for immune checkpoint inhibitors(ICIs).Methods:Relevant literature in the Web of Science core collection database from January 1,2011 to December 31,2023 was searched.Visual analysis was performed on the number of articles,countries,institutions,authors,journals,co-citation,keyword cluster,keyword bursts analysis and theme trend of the included literature by CiteSpace(6.3.1),VOSviewer(v1.6.20),R-bibliometrix(v4.3.3),and Microsoft Excel(2019).Results and Conclusion:1262 references were ultimately included.The number of annual publications and citations has shown a rapid upward trend.The country with the highest number of publications was United States followed by China.Moreover,China’s annual publications had surpassed that of the United States since 2022,but the average citation frequency is relatively low.The global pharmacoeconomic research on ICIs shows regional differences,with some developing countries in Asia,Africa,and South America still blank.The institutions with the highest and second-highest number of publications were the two leading global biopharmaceutical companies,Bristol Myers Squibb and Merck.It can be seen from keyword cluster,keyword bursts and theme trend map that,at present,most of the research topics in ICIs are pharmacoeconomic model studies and patient health-related quality of life studies.In recent years,more pharmacoeconomic research on domestically produced innovative drugs in China had been published.In the future,cost-effectiveness comparisons between different ICIs and different combination therapy regimens can be conducted to provide references for patients’rational drug use.What’s more,real world data can also be used as a basis for government decision-making such as comprehensive drug value assessment a

关 键 词：免疫检查点抑制剂 药物经济学 免疫治疗 文献计量学 可视化分析 

分 类 号：R95[医药卫生—药学]